Acute heart failure (HF) admissions are common. They are often associated with prolonged hospitalisations and poor outcomes. One-third of chronic HF patients also suffer from chronic kidney disease (CKD). Hence, acute admissions of HF with CKD are common and are associated with longer length of stay and increased mortality. Hyperkalaemia and acute on chronic renal impairment are important challenges in the management of these cases. Cautious introduction of high-dose diuretic therapy, followed by the re-commencement of renin-angiotensin-aldosterone (RAAS) inhibitors, improves length of stay, quality of life, and prognosis. During an admission on to the medical assessment unit careful monitoring and management of the patient’s clinical condition and biochemistry is essential.

[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]

References

1. Shurrab M, Ko DT, Zayed Y, et al. Outcomes of ICDs and CRTs in patients with chronic kidney disease: a meta-analysis of 21,000 patients. J Interv Card Electrophysiol. 2018 Oct;53(1):123-9.
2. Jenkins R, Mandarano L, Gugathas S, et al. Impaired renal function affects clinical outcomes and management of patients with heart failure. ESC Heart Fail. 2017 Nov;4(4):576-84.
3. Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014 Feb;35(7):455-69.
4. 4. Banerjee D, Ma JZ, Collins AJ, et al. Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol. 2007 Nov;2(6):1186-90.
5. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002 Jun;8(3):136-41.
6. Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015 Jun 14;36(23):1437-44.
7. Palmer JB, Friedman HS, Waltman Johnson K, et al. Association of persistent and transient worsening renal function with mortality risk, readmissions risk, length of stay, and costs in patients hospitalized with acute heart failure. Clinicoecon Outcomes Res. 2015 Jun 19;7:357-67.
8. Krishnamoorthy A, Greiner MA, Sharma PP, et al. Transient and persistent worsening renal function during hospitalization for acute heart failure. Am Heart J. 2014 Dec;168(6):891-900.
9. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364(9):797-805.
10. SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):293-302.
11. SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992 Sep 3;327(10):685-91.
12. Testani JM, Kimmel SE, Dries DL, et al. Prognostic importance of early worsening renal function after initiation of angiotensinconverting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail. 2011 Nov;4(6):685-91.
13. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012 Dec 13;367(24):2296-304.
14. Greene SJ, Gheorghiade M, Vaduganathan M, et al. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013 Dec;15(12):1401-11.
15. Lu R, Mucino-Bermejo MJ, Ribeiro LC, et al. Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review. Cardiorenal Med. 2015 Apr;5(2):145-56.
16. Damman K, Voors AA, Hillege HL, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail. 2010 Sep;12(9):974-82.
17. Testani JM, Damman K. Venous congestion and renal function in heart failure ... it’s complicated. Eur J Heart Fail. 2013 Jun;15(6):599- 601.
18. F Gnanaraj J, von Haehling S, Anker SD, et al. The relevance of congestion in the cardio-renal syndrome. Kidney Int. 2013 Mar;83(3):384-91.
19. Dilley JR, Corradi A, Arendshorst WJ. Glomerular ultrafiltration dynamics during increased renal venous pressure. Am J Physiol. 1983 Jun;244(6):F650-8.
20. Abildgaard U, Amtorp O, Agerskov K, et al. Renal vascular adjustments to partial renal venous obstruction in dog kidney. Circ Res. 1987 Aug;61(2):194-202.
21. Braam B, Cupples WA, Joles JA, et al. Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail Rev. 2012 Mar;17(2):161-75.
22. Aronson D, Abassi Z, Allon E, et al. Fluid loss, venous congestion, and worsening renal function in acute decompensated heart failure. Eur J Heart Fail. 2013 Jun;15(6):637-43.
23. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008 Apr 1;51(13):1268-74.
24. Dormans TP, Gerlag PG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J. 1996 Dec;17(12):1867-74.
25. Knight EL, Glynn RJ, McIntyre KM, et al. Predictors of decreased renal function in patients with heart failure during angiotensinconverting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J. 1999 Nov;138(5 Pt 1):849-55.
26. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 Feb 13;49(6):675-83.
27. Sanchez JE, Rodriguez C, Gonzalez I, et al. Analysis of the advantages of peritoneal dialysis in the treatment of chronic refractory heart failure. Nefrologia. 2010;30(5):487-9.
28. Khalifeh N, Vychytil A, Horl WH. The role of peritoneal dialysis in the management of treatment-resistant congestive heart failure: A European perspective. Kidney Int Suppl. 2006 Nov;(103):S72-5. doi(103):S72-5.
29. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensinaldosterone system inhibitors. Clin J Am Soc Nephrol. 2010 Mar;5(3):531-48.
30. de Brito-Ashurst I, Varagunam M, Raftery MJ, et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009 Sep;20(9):2075-84.
31. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014 Dec 3;312(21):2223-33.
32. Bakris GL, Pitt B, Weir MR, et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14;314(2):151-61.
33. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15;372(3):211-21.
34. Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct;17(10):1057-65.
35. Pitt B, Bushinsky DA, Kitzman DW, et al. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail. 2018 Jun;5(3):257-66.
36. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8.
37. Kovesdy CP, Lott EH, Lu JL, et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation. 2012 Feb 7;125(5):677-84.
38. Dunlap ME, Hauptman PJ, Amin AN, et al. Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry). J Am Heart Assoc. 2017 Aug 3;6(8):10.1161/JAHA.116.005261.
39. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006 Apr 1;97(7):1064-7.
40. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239.
41. Bikdeli B, Strait KM, Dharmarajan K, et al. Intravenous fluids in acute decompensated heart failure. JACC Heart Fail. 2015 Feb;3(2):127-33.
42. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007 Mar 28;297(12):1319-31.
43. Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. Int J Cardiol. 2013 Jul 15;167(1):151-6.
44. Ahmed A, Fonarow GC, Zhang Y, et al. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012 Apr;125(4):399-410.
45. Ahmed A, Rich MW, Zile M, et al. Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med. 2013 Feb;126(2):150-61.
46. Vardeny O, Wu DH, Desai A, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012 Nov 13;60(20):2082-9.
47. Rossignol P, Cleland JG, Bhandari S, et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation. 2012 Jan 17;125(2):271-9.
48. Haynes R, Judge PK, Staplin N, et al. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation. 2018 Oct 9;138(15):1505-14.
49. Damman K, Gori M, Claggett B, et al. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018 Jun;6(6):489-98.
50. Turakhia MP, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018 Jun 21;39(24):2314-25.
51. Goldenberg I, Moss AJ, McNitt S, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol. 2006 Aug 15;98(4):485-90.
52. Hiremath S, Punnam SR, Brar SS, et al. Implantable defibrillators improve survival in end-stage renal disease: results from a multi-center registry. Am J Nephrol. 2010;32(4):305-10.
53. Herzog CA, Li S, Weinhandl ED, et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int. 2005 Aug;68(2):818-25.
54. Chen TH, Wo HT, Chang PC, et al. A meta-analysis of mortality in end-stage renal disease patients receiving implantable cardioverter defibrillators (ICDs). PLoS One. 2014 Jul 18;9(7):e99418.
55. Charytan DM, Patrick AR, Liu J, et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis. 2011 Sep;58(3):409-17.
56. Boerrigter G, Costello-Boerrigter LC, Abraham WT, et al. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail. 2008 Sep;14(7):539-46.
57. Bazoukis G, Letsas KP, Korantzopoulos P, et al. Impact of baseline renal function on all-cause mortality in patients who underwent cardiac resynchronization therapy: A systematic review and metaanalysis. J Arrhythm. 2017 Oct;33(5):417-23.
58. Richardson M, Freemantle N, Calvert MJ, et al. Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. Eur Heart J. 2007 Aug;28(15):1827-34.
59. Saxon LA, Bristow MR, Boehmer J, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation. 2006 Dec 19;114(25):2766-72.
60. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49.
61. Garg N, Thomas G, Jackson G, et al. Cardiac resynchronization therapy in CKD: a systematic review. Clin J Am Soc Nephrol. 2013 Aug;8(8):1293-303.